SELECT BIOMARKER ANALYSES OF COMPLETELY RESECTED NSCLC TUMORS FROM ENROLLED PATIENTS IN AN ADJUVANT ERLOTINIB (TARCEVA®) CLINICAL TRIAL (RADIANT)

被引：0
|
作者：
Richardson, Frank [1 ]
Richardson, Katherine [2 ]
Young, David [3 ]
Sennello, Regina [4 ]
Horan, Julie [5 ]
Davies, Angela [4 ]
Crino, Lucio [6 ]
Krzakowski, Maciej [7 ]
Hoffman, Philip [8 ]
Chang, Gee Chen [9 ]
O'Orian, Mary [10 ]
Kim, Hoon-Kyo [11 ]
Cho, Eun Kyung [12 ]
机构：
[1] Osi Pharmaceut, Samm, Farmingdale, NY USA
[2] Transgenomic, Omaha, NE USA
[3] Flagship Biosci, Boulder, CO USA
[4] Osi Pharmaceut, Farmingdale, NY USA
[5] Novella Clin, Durham, NC USA
[6] Osped Perugia, Perugia, Italy
[7] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Royal Marsden Hosp, London, England
[11] Catholic Univ Korea, St Vincent Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Hosp, Songnam, Gyeonggi Do, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Biomarkers; RADIANT; NSCLC Adjuvant; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S397 / S398
页数：2
相关论文
共 50 条
  • [21] ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
    Solomon, B. J.
    Wu, Y-L.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Ahn, J. S.
    Horinouchi, H.
    Hochmair, M. J.
    de Marinis, F.
    Migliorino, M. R.
    Kurochkin, A.
    Harputluoglu, H.
    Planchard, D.
    Korphaisarn, K.
    Han, J-Y.
    Lohmann, T.
    Gavaldon, A. Cardona
    Archer, V. R.
    Nowicka, M.
    Noe, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S775 - S775
  • [22] Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.
    O'Brien, Mary E. R.
    Eberhardt, Wilfried Ernst Erich
    Altorki, Nasser K.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Cho, Eun Kyung
    Kim, Joo-Hang
    Szczesna, Aleksandra
    Hoffman, Philip C.
    Burghuber, Otto
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Park, Jung Wook
    Shepherd, Frances A.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
    Zhou, C.
    Altorki, N.
    Vallieres, E.
    Felip, E.
    Zuo, Y.
    Howland, M.
    Xia, F.
    Hoang, T.
    Sandler, A.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.
    Neal, J. W.
    Pennell, N. A.
    Goodgame, B. W.
    Lanuti, M.
    Heist, R. S.
    Shaw, A. T.
    Temel, J. S.
    Janne, P. A.
    Azzoli, C. G.
    Sequist, L. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer (vol 37, pg 97, 2019)
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Janne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel B.
    Wakelee, Heather A.
    Heist, Rebecca S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Murthy, Sudish
    Lanuti, Michael
    Rusch, Valerie W.
    Kris, Mark G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) : 612 - 612
  • [26] Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Santoro, Armando
    Ross, Paul J.
    Gane, Edward
    Vogel, Arndt
    Jeffers, Michael
    Meinhardt, Gerold
    Pena, Carol Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
    Therasse, P.
    Vansteenkiste, J. F.
    Zielinski, M.
    De Pas, T. M.
    Atanackovic, D.
    Sequist, L. V.
    Vallieres, E.
    Swisher, S.
    Adams, S.
    Passlick, B.
    Eberhardt, W. E. E.
    Grunenwald, D.
    Mok, T.
    Boyer, M.
    Katz, A.
    Douillard, J.
    Debois, M.
    Brichard, V. G.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
    Ou, Wei
    Li, Ning
    Wang, Bao-Xiao
    Zhu, Teng-Fei
    Shen, Zhi-Lin
    Wang, Tao
    Chang, Wu-Guang
    Chang, Zeng-Hao
    Hu, Xin-Xin
    Pu, Yue
    Ding, Lie -Ming
    Wang, Si-Yu
    ECLINICALMEDICINE, 2023, 57
  • [29] CLINICAL OUTCOMES WITH ERLOTINIB IN RELATION TO BIOMARKER STATUS: ANALYSES FROM THE OPEN-LABEL TRUST STUDY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Pirker, R.
    Su, W.
    Rooneem, R.
    Mehic, B.
    Franke, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 100 - 101
  • [30] The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients
    Tsao, M
    Zhu, C
    Livingston, R
    Johnson, D
    Gandara, D
    Viallet, J
    Ding, K
    Seymour, L
    Winton, T
    Shepherd, F
    LUNG CANCER, 2005, 49 : S41 - S41
12345